BTG, Inc. (BTGI) Strengthens Non-Invasive Prenatal Diagnostic Technology Patent Portfolio; Novel cell Differentiation Technique Brings Prenatal Testing From Maternal Blood Closer To Reality 
10/19/2005 5:11:18 PM

BTG (LSE: BGC), the intellectual property and technology commercialization company, announced today that it has strengthened its non-invasive prenatal diagnosis patent portfolio through the acquisition of a novel cellular fetal DNA diagnostic. The technology, developed by Professor Maj Hulten, has the ability to identify fetal DNA from the mixed cell population in the maternal bloodstream. This will allow fetal chromosomes to be investigated for several chromosome disorders, including Trisomy 21 (underlying cause of Down syndrome) from a maternal blood sample, without contamination by maternal chromosomes.